Nymox required to resubmit application to dkma

Irvine, calif., july 16, 2024 (globe newswire) -- nymox pharmaceutical corporation (“nymox”) (otc markets nymxf) announced today that its maa submission to the danish medicines agency (dkma) has run out of time and in order to continue will be required to extend the maa application to dkma by re-submission with a new fee required. as it currently stands the application “does not meet the conditions of the medicines act for issuing a marketing authorization.” although a great number of questions were resolved by the company, there remain further responses required that will require additional cycle time. the company is busy analyzing the approaches that are possible. nymox cannot guarantee that all questions can be resolved. the company believes that it has the data required to formulate the required re-submission.
MAA Ratings Summary
MAA Quant Ranking